Clinical Trials Browser

INDUSTRY × Fallopian Tube Neoplasms × Topotecan × Clear all

NCT07545460 2026-04-22

A Study Comparing BL-M07D1 With Physician's Choice of Chemotherapy in Patients With HER2-Expressing Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer

Phase 3 Not yet recruiting

404 enrolled

Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT06994195 2026-04-20

A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANKU-GYN01)

Phase 3 Recruiting

384 enrolled

Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT07213804 2026-04-17

FRAmework-01

Phase 3 Recruiting

1,080 enrolled

Gynecologic

Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Peritoneal Neoplasms

NCT06619236 2026-03-03

RAINFOL-02

Phase 3 Active not recruiting

530 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06161025 2026-01-12

A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase 2/3 Recruiting

860 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05613088 2025-10-20

A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase 2 Completed

106 enrolled 23 charts

Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05870748 2025-09-23

REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1

Phase 2/3 Terminated

600 enrolled

Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05092360 2025-08-28

ARTISTRY-7

Phase 3 Terminated

456 enrolled 19 charts

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04209855 2025-08-27

MIRASOL

Phase 3 Completed

453 enrolled 18 charts 2 FDA

Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT06751485 2024-12-31

JSKN003 in Platinum-Resistant, Relapsed Epithelial Ovarian Cancer

Phase 3 Not yet recruiting

430 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02584478 2023-11-08

AL3818

Phase 3 Unknown

294 enrolled

Gynecologic

Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT02631876 2020-10-14

FORWARD I

Phase 3 Completed

366 enrolled 20 charts

Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00061308 2017-06-09

Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer

Phase 2 Completed

75 enrolled

Gynecologic

Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms

NCT00770536 2015-09-29

AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR

Phase 1 Completed

103 enrolled

Gynecologic

Carcinoma, Fallopian Tube Neoplasms, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms